Skip to main content Skip to accessibility
This website is not compatible with your web browser. You should install a newer browser. If you live in Jersey and need help upgrading call the States of Jersey web team on 440099.
Government of Jerseygov.je

Information and public services for the Island of Jersey

L'înformâtion et les sèrvices publyis pouor I'Île dé Jèrri

Prescribed List (Jersey) as of !st July 2021

A formal published “Ministerial Decision” is required as a record of the decision of a Minister (or an Assistant Minister where they have delegated authority) as they exercise their responsibilities and powers.

Ministers are elected by the States Assembly and have legal responsibilities and powers as “corporation sole” under the States of Jersey Law 2005 by virtue of their office and in their areas of responsibility, including entering into agreements, and under any legislation conferring on them powers.

An accurate record of “Ministerial Decisions” is vital to effective governance, including:

  • demonstrating that good governance, and clear lines of accountability and authority, are in place around decisions-making – including the reasons and basis on which a decision is made, and the action required to implement a decision

  • providing a record of decisions and actions that will be available for examination by States Members, and Panels and Committees of the States Assembly; the public, organisations, and the media; and as a historical record and point of reference for the conduct of public affairs

Ministers are individually accountable to the States Assembly, including for the actions of the departments and agencies which discharge their responsibilities.

The Freedom of Information Law (Jersey) Law 2011 is used as a guide when determining what information is be published. While there is a presumption toward publication to support of transparency and accountability, detailed information may not be published if, for example, it would constitute a breach of data protection, or disclosure would prejudice commercial interest.

A decision made on 27 May 2021

Decision Reference:  MD-S-2021-0045

Decision Summary Title :

DS Prescribed list as of 1 July 2021

Date of Decision Summary:

25 May 2021

Decision Summary Author:

Policy Principal

Decision Summary:

Public or Exempt?

Public

Type of Report:

Oral or Written?

Written

Person Giving

Oral Report:

NA

Written Report

Title :

WR report PBAC 13 May 2021

Date of Written Report:

25 May 2021

Written Report Author:

Prescribing Advisor

Written Report

Public or Exempt?

 

Public

Supporting Document

Author:

Prescribing Advisor

Supporting Document

Public or Exempt?

 

Exempt FOI Art 33 (b)

Subject: Changes to be made to the Prescribed List (Jersey) as of 1 July 2021

Decision(s): Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List with effect from 1 July 2021 (unless stated otherwise) as set out in the accompanying written report and supporting document.

Reason(s) for Decision: The Pharmaceutical Benefit Advisory Committee met to consider applications for changes to the Prescribed List and made the following recommendations:

1.      Items to be added to the Prescribed List from 1 July 2021

 

1.1  Morphine sulphate 10mg, 30mg, 60mg, 100mg, 200mg modified-release capsules (Zomorph brand)

1.2  Metolazone 2.5mg, 5mg tablets

1.3  Torasemide 2.5mg, 5mg, 10mg tablets

1.4  Bempedoic acid 180mg tablets; bempedoic acid 180mg/ezetimibe 10mg tablets

1.5  Sodium valproate 400mg powder and solvent for solution for injection vials; sodium valproate 300mg/3ml solution for injection ampoules

2.      Items to be removed from the Prescribed List (from 1 October 2021)

 

2.1  Aminophylline 225mg, 350mg modified-release tablets (discontinued)

2.2  Morphine sulphate 20mg, 30mg, 60mg, 100mg, 200mg modified release granules for oral suspension (discontinued)

 

  1. Items not recommended for inclusion in the Prescribed List

 

3.1  Dapoxetine 30mg, 60mg tablets

3.2  Liraglutide 6mg/ml solution for injection 3ml pre-filled disposable devices (Saxenda brand) – licence extension as adjunct to weight management

 

The above recommendations reflect current evidence and expert advice and ensure that patients in Jersey have access to an appropriate range of modern, safe and effective treatments from their GPs and community prescribers at a proportionate cost to the Fund.

Resource Implications: The overall financial impact of the above changes is expected to be a cost increase. The expenditure has been approved by the Minister, presented in a supporting document but not published in accordance with FOI Article 33 (b) as the estimates include a confidential discount.

Action required: Health Zone Manager at Customer and Local Services to issue a public notice listing amendments and notify all approved medical practitioners and approved contractors.

Signature:

 

 

Position:

Minister

 

Date Signed:

 

 

Date of Decision (If different from Date Signed):

 

Back to top
rating button